Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer.

ctDNA was studied as a recurrence-risk marker in people with resectable gastric and gastroesophageal junction adenocarcinoma receiving perioperative chemotherapy. The abstract does not name the assay.

Gastric CancerPubMed 39369091DOI 10.1007/s10120-024-01556-9